Literature DB >> 11861870

Equine infectious anemia virus and the ubiquitin-proteasome system.

David E Ott1, Lori V Coren, Raymond C Sowder, Julian Adams, Kunio Nagashima, Ulrich Schubert.   

Abstract

Some retroviruses contain monoubiquitinated Gag and do not bud efficiently from cells treated with proteasome inhibitors, suggesting an interaction between the ubiquitin-proteasome system and retrovirus assembly. We examined equine infectious anemia virus (EIAV) particles and found that approximately 2% of the p9(Gag) proteins are monoubiquitinated, demonstrating that this Gag protein interacts with an ubiquitinating activity. Different types of proteasome inhibitors were used to determine if proteasome inactivation affects EIAV release from chronically infected cells. Pulse-chase immunoprecipitation and time course immunoblot analyses showed that proteasome inactivation slightly decreased virus release (at most a twofold effect), while it did not affect Gag processing. These results contrast with those obtained with other viruses which are sensitive to these inhibitors. This suggests that, although its Gag is monoubiquitinated, the requirements for EIAV release are somewhat different from those for retroviruses that are sensitive to proteasome inhibitors.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11861870      PMCID: PMC135975          DOI: 10.1128/jvi.76.6.3038-3044.2002

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  53 in total

1.  WW domains and retrovirus budding.

Authors:  L Garnier; J W Wills; M F Verderame; M Sudol
Journal:  Nature       Date:  1996-06-27       Impact factor: 49.962

Review 2.  Ubiquitin-dependent protein degradation.

Authors:  M Hochstrasser
Journal:  Annu Rev Genet       Date:  1996       Impact factor: 16.830

3.  Cytoskeletal proteins inside human immunodeficiency virus type 1 virions.

Authors:  D E Ott; L V Coren; B P Kane; L K Busch; D G Johnson; R C Sowder; E N Chertova; L O Arthur; L E Henderson
Journal:  J Virol       Date:  1996-11       Impact factor: 5.103

4.  An assembly domain of the Rous sarcoma virus Gag protein required late in budding.

Authors:  J W Wills; C E Cameron; C B Wilson; Y Xiang; R P Bennett; J Leis
Journal:  J Virol       Date:  1994-10       Impact factor: 5.103

5.  Fine mapping and characterization of the Rous sarcoma virus Pr76gag late assembly domain.

Authors:  Y Xiang; C E Cameron; J W Wills; J Leis
Journal:  J Virol       Date:  1996-08       Impact factor: 5.103

6.  Cell membrane vesicles are a major contaminant of gradient-enriched human immunodeficiency virus type-1 preparations.

Authors:  P Gluschankof; I Mondor; H R Gelderblom; Q J Sattentau
Journal:  Virology       Date:  1997-03-31       Impact factor: 3.616

7.  Microvesicles are a source of contaminating cellular proteins found in purified HIV-1 preparations.

Authors:  J W Bess; R J Gorelick; W J Bosche; L E Henderson; L O Arthur
Journal:  Virology       Date:  1997-03-31       Impact factor: 3.616

8.  Factors underlying spontaneous inactivation and susceptibility to neutralization of human immunodeficiency virus.

Authors:  S P Layne; M J Merges; M Dembo; J L Spouge; S R Conley; J P Moore; J L Raina; H Renz; H R Gelderblom; P L Nara
Journal:  Virology       Date:  1992-08       Impact factor: 3.616

9.  High levels of HIV-1 in plasma during all stages of infection determined by competitive PCR.

Authors:  M Piatak; M S Saag; L C Yang; S J Clark; J C Kappes; K C Luk; B H Hahn; G M Shaw; J D Lifson
Journal:  Science       Date:  1993-03-19       Impact factor: 47.728

10.  Nucleocapsid zinc fingers detected in retroviruses: EXAFS studies of intact viruses and the solution-state structure of the nucleocapsid protein from HIV-1.

Authors:  M F Summers; L E Henderson; M R Chance; J W Bess; T L South; P R Blake; I Sagi; G Perez-Alvarado; R C Sowder; D R Hare
Journal:  Protein Sci       Date:  1992-05       Impact factor: 6.725

View more
  41 in total

Review 1.  Viral late domains.

Authors:  Eric O Freed
Journal:  J Virol       Date:  2002-05       Impact factor: 5.103

2.  Role of ESCRT-I in retroviral budding.

Authors:  Juan Martin-Serrano; Trinity Zang; Paul D Bieniasz
Journal:  J Virol       Date:  2003-04       Impact factor: 5.103

3.  The C-terminal half of TSG101 blocks Rous sarcoma virus budding and sequesters Gag into unique nonendosomal structures.

Authors:  Marc C Johnson; Jared L Spidel; Danso Ako-Adjei; John W Wills; Volker M Vogt
Journal:  J Virol       Date:  2005-03       Impact factor: 5.103

4.  Evidence for a new viral late-domain core sequence, FPIV, necessary for budding of a paramyxovirus.

Authors:  Anthony P Schmitt; George P Leser; Eiji Morita; Wesley I Sundquist; Robert A Lamb
Journal:  J Virol       Date:  2005-03       Impact factor: 5.103

5.  Ubiquitin-dependent virus particle budding without viral protein ubiquitination.

Authors:  Maria Zhadina; Myra O McClure; Marc C Johnson; Paul D Bieniasz
Journal:  Proc Natl Acad Sci U S A       Date:  2007-12-03       Impact factor: 11.205

6.  YRKL sequence of influenza virus M1 functions as the L domain motif and interacts with VPS28 and Cdc42.

Authors:  Eric Ka-Wai Hui; Subrata Barman; Dominic Ho-Ping Tang; Bryan France; Debi P Nayak
Journal:  J Virol       Date:  2006-03       Impact factor: 5.103

7.  Intracellular trafficking and maturation of herpes simplex virus type 1 gB and virus egress require functional biogenesis of multivesicular bodies.

Authors:  Arianna Calistri; Paola Sette; Cristiano Salata; Enrico Cancellotti; Cristina Forghieri; Alessandra Comin; Heinrich Göttlinger; Gabriella Campadelli-Fiume; Giorgio Palù; Cristina Parolin
Journal:  J Virol       Date:  2007-08-08       Impact factor: 5.103

8.  Ubiquitination of the prototype foamy virus envelope glycoprotein leader peptide regulates subviral particle release.

Authors:  Nicole Stanke; Annett Stange; Daniel Lüftenegger; Hanswalter Zentgraf; Dirk Lindemann
Journal:  J Virol       Date:  2005-12       Impact factor: 5.103

9.  Divergent retroviral late-budding domains recruit vacuolar protein sorting factors by using alternative adaptor proteins.

Authors:  Juan Martin-Serrano; Anton Yarovoy; David Perez-Caballero; Paul D Bieniasz; Anton Yaravoy
Journal:  Proc Natl Acad Sci U S A       Date:  2003-09-30       Impact factor: 11.205

10.  Functional replacement of a retroviral late domain by ubiquitin fusion.

Authors:  Anjali Joshi; Utpal Munshi; Sherimay D Ablan; Kunio Nagashima; Eric O Freed
Journal:  Traffic       Date:  2008-08-09       Impact factor: 6.215

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.